| 5.4 0.11 (2.08%) | 07-28 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 7.28 | 1-year : | 8.17 |
| Resists | First : | 6.23 | Second : | 7 |
| Pivot price | 5.72  |
|||
| Supports | First : | 5 | Second : | 4.15 |
| MAs | MA(5) : | 5.38 |
MA(20) : | 5.81 |
| MA(100) : | 5.99 |
MA(250) : | 5.9 |
|
| MACD | MACD : | -0.3 |
Signal : | -0.2 |
| %K %D | K(14,3) : | 13.9 |
D(3) : | 14.9 |
| RSI | RSI(14): 43.1 |
|||
| 52-week | High : | 9.82 | Low : | 3.27 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ VRCA ] has closed above bottom band by 31.1%. Bollinger Bands are 3.3% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 5.87 - 5.89 | 5.89 - 5.91 |
| Low: | 5.32 - 5.34 | 5.34 - 5.37 |
| Close: | 5.36 - 5.39 | 5.39 - 5.44 |
Verrica Pharmaceuticals Inc., a dermatology therapeutics company, engages in the development and commercialization of medications for the treatment of dermatologic diseases in the United States. The company offers YCANTH (VP-102) a drug-device combination that contains a GMP-controlled formulation of cantharidin for the treatment of molluscum in adult and pediatric patients, as well as for the treatment of common warts. It also develops VP-315, an oncolytic peptide-based injectable therapy that is in phase II clinical trial for the treatment of dermatology oncologic conditions, which include basal cell carcinoma and other dermatological oncology indications. The company has a collaboration and license agreement with Torii Pharmaceutical Co., Ltd. for the development and commercialization of its product candidates for the treatment of molluscum and common warts in Japan; and a license agreement with Lytix Biopharma AS to develop and commercialize VP-315 for use in malignant and pre-malignant dermatological indications. Verrica Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in West Chester, Pennsylvania.
Tue, 28 Jul 2026
Verrica Pharmaceuticals Inc (VRCA) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Tue, 28 Jul 2026
Verrica Pharmaceuticals Inc (VRCA) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Mon, 27 Jul 2026
VRCA|Verrica Pharmaceuticals Inc|Price:5.820|Chg%:+0.470 - TradingKey
Fri, 24 Jul 2026
Verrica Pharmaceuticals Inc. Revenue Breakdown – NASDAQ:VRCA - TradingView
Tue, 21 Jul 2026
Verrica deal could bring YCANTH to Israeli children if approved - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 17 (M) |
| Shares Float | 8 (M) |
| Held by Insiders | 48.7 (%) |
| Held by Institutions | 27.8 (%) |
| Shares Short | 316 (K) |
| Shares Short P.Month | 352 (K) |
| EPS | -1.11 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.93 |
| Profit Margin | -48 % |
| Operating Margin | -193.5 % |
| Return on Assets (ttm) | -20.9 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 46 % |
| Gross Profit (p.s.) | 1.32 |
| Sales Per Share | 2.16 |
| EBITDA (p.s.) | -0.77 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -14 (M) |
| Levered Free Cash Flow | -12 (M) |
| PE Ratio | -4.91 |
| PEG Ratio | 0 |
| Price to Book value | 5.74 |
| Price to Sales | 2.49 |
| Price to Cash Flow | -6.58 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|